Literature DB >> 8418252

A PET radiotracer for studying serotonin uptake sites: carbon-11-McN-5652Z.

M Suehiro1, U Scheffel, R F Dannals, H T Ravert, G A Ricaurte, H N Wagner.   

Abstract

A radioligand for imaging central serotonin (5-hydroxytryptamine; 5-HT) uptake sites by positron emission tomography (PET) has yet to be developed. Such a tracer would be useful for the study of normal and altered serotonergic neurotransmission as well as for the detection of serotonergic neurotoxicity. This paper describes the labeling of the highly potent serotonin (5-HT) uptake blocker, McN-5652-Z (trans-1,2,3,5,6,10 beta-hexahydro-6-[4-(methylthio)phenyl]pyrrolo-[2,1-a]-isoquinoline; racemic mixture), with 11C and the evaluation of this radiotracer in rodents with respect to its in vivo binding characteristics. In mouse brain, 11C-McN-5652-Z accumulated rapidly in regions with high densities of 5-HT uptake sites. The ratio between hypothalamus and cerebellum was 1.5:1 at 15 min and increased with time to 4.6:1 at 90 min after injection. The distribution of 11C-McN-5652 in rat brain at 60 min correlated well with regional concentrations of 5-HT uptake sites (r = 0.86). The specificity and selectivity of 11C-McN-5652 binding to the 5-HT transporter were tested by preinjecting blocking doses of known 5-HT, dopamine and norepinephrine uptake inhibitors, and a 5-HT2 receptor blocker before injection of the radiotracer. Preinjection of increasing doses of unlabeled McN-5652-Z inhibited 11C-McN-5652-Z binding in a dose-dependent fashion. These results suggest that the in vivo binding of the radiotracer was specific, selective for 5-HT uptake sites, saturable and that 11C-McN-5652-Z holds promise as a radiotracer for PET imaging of 5-HT uptake sites in the mammalian brain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8418252

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.

Authors:  Jeffrey S Stehouwer; Mark M Goodman
Journal:  PET Clin       Date:  2009-01

2.  In vitro and in vivo characterisation of nor-beta-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain.

Authors:  K A Bergström; C Halldin; H Hall; C Lundkvist; N Ginovart; C G Swahn; L Farde
Journal:  Eur J Nucl Med       Date:  1997-06

3.  Kinetic analysis of [11C]McN5652: a serotonin transporter radioligand.

Authors:  Z Szabo; U Scheffel; W B Mathews; H T Ravert; K Szabo; M Kraut; S Palmon; G A Ricaurte; R F Dannals
Journal:  J Cereb Blood Flow Metab       Date:  1999-09       Impact factor: 6.200

4.  Low brain serotonin transporter binding in major depressive disorder.

Authors:  Andrew B Newberg; Jay D Amsterdam; Nancy Wintering; Justine Shults
Journal:  Psychiatry Res       Date:  2012-06-12       Impact factor: 3.222

5.  PET∕CT imaging evidence of FUS-mediated (18)F-FDG uptake changes in rat brain.

Authors:  Hyungmin Kim; Mi-Ae Park; Shuyan Wang; Alan Chiu; Krisztina Fischer; Seung-Schik Yoo
Journal:  Med Phys       Date:  2013-03       Impact factor: 4.071

6.  Positron emission tomography imaging of the serotonin transporter and 5-HT(1A) receptor in alcohol dependence.

Authors:  Diana Martinez; Mark Slifstein; Roberto Gil; Dah-Ren Hwang; Yiyun Huang; Audrey Perez; W Gordon Frankle; Marc Laruelle; John Krystal; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2008-10-29       Impact factor: 13.382

7.  Radiosynthesis of [(131)I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker - is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker?

Authors:  Makiko Suehiro; Paul Burgman; Sean Carlin; Sean Burke; Guangbin Yang; Ouathek Ouerfelli; Christoph Oehler-Janne; Joseph O'Donoghue; Clifton Ling; John Humm
Journal:  Nucl Med Biol       Date:  2009-05-07       Impact factor: 2.408

8.  Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM.

Authors:  N Herold; K Uebelhack; L Franke; H Amthauer; L Luedemann; H Bruhn; R Felix; R Uebelhack; M Plotkin
Journal:  J Neural Transm (Vienna)       Date:  2006-02-09       Impact factor: 3.850

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.